Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.

ABSTRACT:

Background

Pemetrexed, a multitargeted antifolate drug, is an active agent in non-small-cell lung cancer (NSCLC), especially adenocarcinomas. Based on preclinical data supporting the relevance of alpha-folate receptors in adenocarcinoma of the bronchioloalveolar carcinoma (BAC) subtype, this trial was designed to assess pemetrexed in patients with this pathologic subtype of lung adenocarcinoma.

Patients and methods

Patients with histologically confirmed stage IIIB (with malignant pleural effusion) or stage IV adenocarcinoma with BAC features or pure BAC were eligible. Treatment consisted of pemetrexed, 500 mg/m(2), administered intravenously every 21 days.

Results

Of 27 patients enrolled, 24 were eligible and assessable for adverse events: Toxicity was primarily hemat

SUBMITTER: Lau DH 

PROVIDER: S-EPMC4567037 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature